GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major infectious disease.
The UK drugmaker said on Friday that an interim analysis showed statistically meaningful efficacy and no safety concerns for the vaccine.
Vaccine makers including GSK, Pfizer, Moderna and Johnson & Johnson, are racing to find a jab for RSV. The disease is common but can be severe in older adults and infants, causing 360,000 hospitalisations and 24,000 deaths a year.
您已閱讀24%（591字），剩餘76%（1862字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。